Inovio Pharmaceuticals
INOINO · Stock Price
Historical price data
Overview
Inovio Pharmaceuticals is a U.S.-based clinical-stage biotech focused on developing DNA-based immunotherapies and vaccines. Its core strategy leverages a proprietary two-part platform—SynCon® for plasmid design and CELLECTRA® for delivery—to advance a pipeline targeting HPV-related diseases, cancer, and infectious diseases. The company's most significant near-term catalyst is the FDA review of its Biologics License Application (BLA) for INO-3107 in recurrent respiratory papillomatosis (RRP), which represents a potential first-in-class DNA medicine approval. With a seasoned leadership team and a history of strategic partnerships, Inovio is positioning itself at the forefront of nucleic acid therapeutics.
Technology Platform
Proprietary DNA medicine platform combining SynCon® for computer-designed plasmid optimization and CELLECTRA® for electroporation-based intracellular delivery, enabling in vivo production of therapeutic proteins.
Pipeline
47| Drug | Indication | Stage | Watch |
|---|---|---|---|
| VGX-3100 + Placebo | Cervical Dysplasia | Phase 3 | |
| VGX-3100 + Matched Placebo | Cervical Dysplasia | Phase 3 | |
| INO-4800 + Placebo | Coronavirus Infection | Phase 2/3 | |
| INO-3112 vaccine + Cisplatin chemotherapy | Uterine Cervical Neoplasms | Phase 2 | |
| INO-4700 + Placebo + INO-4700 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) | Phase 2 |
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Faces competition in HPV space from surgery, checkpoint inhibitors, and other therapeutic vaccines. Platform competes with dominant mRNA/LNP technologies (Moderna, BioNTech) and viral gene therapies, differentiating via electroporation delivery and a focus on potent T-cell responses without viral vectors or LNPs.